Feb 07, 2018
Time to Elevate Protection in Haemophilia Care: New Data From Sobi(TM)
Feb 07, 2018
The Republic of Ireland Switches all People With Haemophilia A & B Treated With Replacement Clotting Factors to Sobi's(TM) Extended Half-life Therapies
Jan 09, 2018
rHEALTH Achieves CE Mark for its Factor VIII Test Kit
Dec 19, 2017
BioMarin Doses First Patient in Global GENEr8-1 Phase 3 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
Dec 11, 2017
BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia (ASH) Meeting
Dec 09, 2017
New Therapies Improve Outlook for Bleeding and Clotting Disorders
Dec 09, 2017
BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting Concurrent with NEJM Publication
Dec 06, 2017
BioMarin Announces Presentations at 59th American Society of Hematology Annual Meeting & Exposition
Nov 16, 2017
FDA approves new treatment to prevent bleeding in certain patients with hemophilia A
Oct 30, 2017
Bayer Announces BAY94-9027 Biologics License Application Accepted by U.S. Food & Drug Administration
Oct 27, 2017
The First Patient Enrolled in the ReITIrate Study Evaluating Immune Tolerance Induction With Elocta®
Oct 26, 2017
FDA Grants Breakthrough Therapy Designation for BioMarin's Valoctocogene Roxaparvovec (formerly BMN 270), an Investigational Gene Therapy for Hemophilia A
Sep 28, 2017
Japan's Ministry of Health, Labour and Welfare Approves AFSTYLA® - CSL Behring's Novel Recombinant Haemophilia A Treatment
Sep 22, 2017
World Bleeding Disorders Treatment Market 2017-2027
Aug 02, 2017
BioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therapy for Hemophilia A, into Phase 3 Studies
Jun 22, 2017
Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease
Jun 16, 2017
BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis 2017 Congress
May 31, 2017
Hemophilia A Therapeutics Pipeline (Hematological Disorders) Review H1 2017 Market Report